Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study
Jacoline E.C. Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C. Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein W.M. van der Poel, Wendy B.C. Stevens, Josee M. Zijlstra, Dieta Brandsma, Marcel Nijland, Kylie D. Mason, Aart Beeker, Martine C.J. Abrahamse-Testroote, Martin J. van den Bent, Daphne de Jong, Jeanette K. Doorduijn
Dive into the research topics of 'Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study'. Together they form a unique fingerprint.